Can THEM6 targeting stop resistance to prostate cancer treatment?
Abstract Prostate cancer (PCa) clinical management relies heavily on androgen‐deprivation therapy (ADT). However, despite experiencing initial clinical benefit, patients getting ADT for non‐resectable PCa eventually relapse and develop fatal castration‐resistant PCa (CRPC). Multiple mechanisms of ac...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer Nature
2022-02-01
|
| Series: | EMBO Molecular Medicine |
| Online Access: | https://doi.org/10.15252/emmm.202115504 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|